VANCOUVER, BC, June 2, 2025 /PRNewswire/ - As new U.S. tariffs hit medical devices and equipment, raw materials, and essential components, iData Research warns of significant cost escalation and supply disruption across the MedTech sector. A recent U.S. court decision blocking the bulk of the proposed tariffs has only added further uncertainty, leaving manufacturers and suppliers navigating shifting trade policies with little clarity. With import duties potentially reaching up to 145%, and the

NASHVILLE, Tenn. and SAN ANTONIO, June 2, 2025 /PRNewswire/ -- OneOncology, a physician-led national platform empowering independent oncology practices, and The START Center for Cancer Care, a physician-owned oncology practice with 44 providers treating patients at six clinics, have finalized a partnership agreement that will enhance the delivery of cancer care services across the San Antonio region. Continue Reading The START Center for Cancer Care has 37 physicians, seven advanced practice pro

Up to $142 million announced for research group that includes MIT and Stanford TEMPE, Ariz., June 2, 2025 /PRNewswire/ -- Every year, about 2 million Americans are diagnosed with cancer and more than 600,000 of them have cancer that spreads or no longer responds to treatment because of cancer cell mutations. Researchers at Arizona State University aim to solve this by making cancer care more personal, helping doctors adapt treatments to patients' changing cancers. The Advanced Research Project

Ensures Increased Durability and Versatility for High-sensitivity Biomarker Analysis TORRANCE, Calif., June 2, 2025 /PRNewswire/ -- Phenomenex Inc., a Danaher Company, a global leader in the research and manufacture of advanced technologies for the separation sciences, has announced the expansion of its product portfolio at ASMS with the introduction of 0.15 mm ID Micro LC Columns and Micro Traps, specifically designed for low-flow applications. The new core-shell based micro columns are designe

NEWTON, Mass., June 2, 2025 /PRNewswire/ -- GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel from the Angeles Clinic and Research Institute presented updated clinical and translational data of GV20-0251 monotherapy from the ongoing Phase 1/2 clinical trial evaluating GV20-0251 in patients with advanced solid tumors resistant to anti-PD(L)1 and other standard therapies (NCT05669430) at the American Society of Clinical Oncol

Funds from the Two-Phase Fast-Track SBIR Grant, Combined, Would Total Approximately $2.9 Million DALLAS, June 2, 2025 /PRNewswire/ -- Berkshire Biomedical Corporation ("Berkshire" or "the Company"), focused on developing its proprietary drug dispensing technology to enhance patient wellness, today announced that it has been awarded the first phase of a two-phase Fast-Track Small Business Innovation Research (SBIR) grant (1 R44DA061908-01A1) from the National Institutes of Health's (NIH) Nationa

NEW YORK, NY, USA and MAINZ, GERMANY I May 28, 2025 I Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that they have submitted a regulatory application to the European Medicines Agency (EMA) for approval of COMIRNATY ® for the 2025-2026 season, targeting the LP.8.1 strain. The submission follows the recommendation by the EMA’s Emergency Task Force (ETF) to update the COVID-19 vaccine composition for the coming season to target the LP.8.1 strain. The C

MAINZ, Germany, and PRINCETON, NJ, USA I June 2, 2025 I BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced that the companies have entered into an agreement for the global co-development and co-commercialization of BioNTech’s investigational bispecific antibody BNT327 across numerous solid tumor types. Under the agreement, BioNTech and BMS will work jointly to broaden and accelerate the development of this clinical candidate. BioNTech’s BNT327, a n

INDIANAPOLIS, June 2, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new Phase 1 data showing that its folate receptor alpha (FRα) antibody-drug conjugate (ADC) (LY4170156) demonstrated an encouraging safety profile and anti-tumor activity across dose and FRα expression levels in women with heavily pre-treated platinum-resistant ovarian cancer, including patients previously treated with mirvetuximab soravtansine. A preliminary overall objective response rate (ORR) of 55%

-Clinical benefit and favorable safety profile as monotherapy and in combination with SOC- -Biomarker data supports MOA: decreased GBM mesenchymal signature and increased TME immune activity- TARRYTOWN, N.Y., June 2, 2025 /PRNewswire/ -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today announced updated positive clinical and biomarker data fr